Skip to main content

Table 1 Comparisons of demographic and clinical characteristics between D2T and non-D2T groups in KOBIO registry

From: Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry

Variable

Total (n = 2,321)

D2T (n = 271)

Non-D2T (n = 2,050)

p-value

Demographics

 Age, years, mean (SD)

54.6 (12.8)

53.8 (12.4)

54.8 (12.9)

0.240

 Sex, N (%)

   

0.148

  Male

407 (17.5)

39 (14.4)

368 (18.0)

 

  Female

1,914 (82.5)

232 (85.6)

1,682 (82.1)

 

 BMI, mean (SD)

22.8 (3.5)

22.7 (3.7)

22.8 (3.5)

0.632

 Smoking, N (%)

   

0.973

  Ex-smoker

215 (9.3)

26 (9.6)

189 (9.2)

 

  Current smoker

185 (8.0)

21 (7.8)

164 (8.0)

 

  Never

1,921 (82.8)

224 (82.7)

1,697 (82.8)

 

Comorbidities

 Diabetes mellitus, N (%)

290 (12.5)

33 (12.2)

257 (12.5)

0.866

 Hypertension, N (%)

703 (30.3)

83 (30.6)

620 (30.2)

0.897

 Cardiovascular disease, N (%)

597 (25.7)

88 (32.5)

509 (24.8)

0.007

 Cancer, N (%)

10 (0.4)

2 (0.7)

8 (0.4)

0.329

Extraarticular manifestations

 Scleritis or episcleritis, N (%)

5 (0.2)

0 (0.0)

5 (0.2)

-

 Secondary Sjogren’s syndrome, N (%)

71 (3.1)

5 (1.9)

66 (3.2)

0.217

 Subcutaneous rheumatoid nodule, N (%)

55 (2.4)

12 (4.4)

43 (2.1)

0.018

 Cutaneous vasculitis, N (%)

4 (0.2)

1 (0.4)

4 (0.2)

0.393

 Pleuritis, N (%)

9 (0.4)

1 (0.4)

8 (0.4)

-

 Interstitial lung disease, N (%)

140 (6.0)

22 (8.1)

118 (5.8)

0.128

Disease status

 Disease duration, years, median [IQR]

5.6 [1.8, 11.9]

9.7 [5.2, 15.2]

5 [1.6, 11.2]

< 0.001

 RF positivity, N (%)

1,854 (82.9)

201 (79.1)

1,653 (83.4)

0.089

 Anti-CCP Ab positivity, N (%)

1,671 (85.8)

170 (84.6)

1,501 (85.9)

0.606

 Tender joint count, median [IQR]

7 [4, 12]

8 [4, 14]

7 [4, 11]

0.073

 Swollen joint count, median [IQR]

6 [3, 9]

6 [3, 10]

5 [2, 9]

0.144

 Patient global assessment, mean (SD)

6.83 (2.04)

7.01 (1.99)

6.81(2.04)

0.130

 Physician global assessment, mean (SD)

6.47 (1.82)

6.71 (1.69)

6.44 (1.84)

0.024

 ESR, mm/hr, median [IQR]

44 [28, 65]

47 [29, 75]

44 [28, 65]

0.055

 CRP, mg/dL, median [IQR]

1.25 [0.43, 2.93]

1.72 [0.34, 3.78]

1.21 [0.44, 2.80]

0.033

 DAS28-ESR, mean (SD)

5.52 (1.14)

5.65 (1.15)

5.51 (1.13)

0.062

 DAS28-CRP, mean (SD)

4.83 (1.13)

4.98 (1.16)

4.81 (1.12)

0.020

 SDAI, mean (SD)

28.9 (11.8)

31.1 (12.9)

28.6 (11.6)

0.003

 CDAI, mean (SD)

26.7 (11.0)

28.2 (11.9)

26.4 (10.9)

0.02

 Radiographic erosions, N (%)

889 (38.3)

100 (36.9)

789 (38.5)

0.613

Function

 RAPID3, mean (SD)

15.3 (5.7)

16.8 (5.5)

15.1 (5.6)

< 0.001

  1. The data are included at starting new b/tsDMARDs. Data were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR) as appropriate, or frequency (percentage). P-values are calculated using chi square test, Student’s t-test, or Wilcoxon rank-sum test. Bold values indicate significant p-values
  2. RA rheumatoid arthritis, KOBIO Korean Rheumatology Biologics registry, BMI body mass index, RF rheumatoid factor, Anti-CCP Ab anti-citrullinated protein antibody, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS disease activity score, VAS visual analogue scale, ILD interstitial lung disease, csDMARDs conventional synthetic disease modifying anti-rheumatic drugs, IQR inter-quartile range, TNF tumor necrosis factor, D2T difficult to treat
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us